Results from the Reducing with Metformin Vascular Adverse Lesions (REMOVAL) study show for the first time that metformin has a cardiovascular benefit in patients with type 1 diabetes mellitus (T1DM), although the benefit was limited to tertiary outcomes and was modest. Additional measures are therefore needed to reduce cardiovascular disease in patients with T1DM.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Livingstone, S. J. et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med. 9, e1001321 (2012).
Rawshani, A. et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N. Engl. J. Med. 376, 1407–1418 (2017).
Lachin, J. M., Orchard, T. J., Nathan, D. M. & DCCT/EDIC Research Group. Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37, 39–43 (2014).
Schauer, I. E. et al. Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: the CACTI study. Diabetes 60, 306–314 (2011).
Petrie, J. R. et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 5, 597–609 (2017).
Nadeau, K. J. et al. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J. Clin. Endocrinol. Metab. 95, 513–521 (2010).
Yki-Järvinen, H. & Koivisto, V. A. Natural course of insulin resistance in type I diabetes. N. Engl. J. Med. 315, 224–230 (1986).
[No authors listed.] Standards of medical care in diabetes — 2017: summary of revisions. Diabetes Care 40, S4–S5 (2017).
Livingstone, S. J. et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA 313, 37–44 (2015).
Kaul, S. Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials. Diabetes Care 40, 821–831 (2017).
Acknowledgements
Support for this study was provided by National Heart, Lung, and Blood Institute grant R01 HL113029 and American Diabetes Association grant 7-13-CD-10.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Snell-Bergeon, J. Cardiovascular benefits of metformin in T1DM. Nat Rev Endocrinol 13, 565–566 (2017). https://doi.org/10.1038/nrendo.2017.116
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2017.116
This article is cited by
-
The function, mechanisms, and clinical applications of metformin: potential drug, unlimited potentials
Archives of Pharmacal Research (2023)